RecruitingPhase 4NCT04490031
Evaluation of Ketamine as Sedative Agent in Endoscopic Retrograde Cholangiopancreatography (ERCP)
Randomized Control Study Evaluating Ketamine as Sedative Agent in Endoscopic Retrograde Cholangiopancreatography (ERCP)
Sponsor
Universiti Kebangsaan Malaysia Medical Centre
Enrollment
140 participants
Start Date
Mar 1, 2020
Study Type
INTERVENTIONAL
Conditions
Summary
This is a study evaluating the usage of Ketamine as sedative agent in ERCP. The usage of Ketamine will be compared to the standard sedation in our center, which is Midazolam in combination with Pethidine as analgesia.
Eligibility
Min Age: 16 Years
Inclusion Criteria2
- Malaysian citizens of who is able to give valid consent
- Patient planned for ERCP (either emergency or elective)
Exclusion Criteria10
- Known hypersensitivity towards Ketamine or Midazolam
- Patient refusal to participate or unable to give consent
- Increased intracranial pressure, acute stroke (<3 months), intracranial haemorrhage (<3 months)
- Uncontrolled hypertension (BP>160/100) and tachycardia (Heart rate >120)
- Acute myocardial infarction, acute coronary syndrome (<3 months)
- Tachyarrythmia
- Pregnancy
- IVDU or substance abuse patient
- Patient with history of hallucination
- Child's Pugh Class C
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGKetamine Hydrochloride
patient in Ketamine group will be given Ketamine as sedative agent
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04490031